Rezolute reports Q1 FY2026 net loss $18.2M; Phase 3 sunRIZE topline due Dec 2025

Rezolute, Inc.

2026-Q1 EPS reported -$0.18 vs consensus -$0.18 ▲ beat (+1.4%)

Cash & marketable securities $152.2M as of Sep 30, 2025, down from $167.9M on Jun 30.
Net loss $18.2M for Q1 FY2026 vs $15.4M a year ago; R&D $13.1M, G&A $6.7M.
Phase 3 sunRIZE (congenital HI) topline results expected December 2025; registrational alignment with FDA.
Streamlined single-arm Phase 3 upLIFT (tumor HI) enrollment underway; topline data H2 2026.
Virtual investor event Nov 10, 2025 featuring KOLs on commercial opportunity for ersodetug.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.